Blog
Semax: Research Overview
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragment 4-10, studied for its interactions with neuronal gene expression and injury-response pathways in animal models.
A study examined the genome-wide transcriptomic response of ischemic rat brain cortex to Semax in an animal model of permanent middle cerebral artery occlusion, comparing Semax-treated and saline-treated rats at 3 and 24 hours after occlusion; Semax was associated with altered expression of genes predominantly linked to immune responses, including immunoglobulins and chemokines, in the ischemic cortical tissue examined (PMC).
A related study published in the International Journal of Molecular Sciences (2021), titled “Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia–Reperfusion,” examined Semax in an animal model of transient middle cerebral artery occlusion and reperfusion in male Wistar rats, reporting changes in brain protein expression profiles at 24 hours after occlusion (PMC).
For laboratory research use only — not for human consumption. This content is presented for educational and informational purposes and is not intended as medical advice, a treatment claim, or usage instruction.
